Northwestern Mutual Wealth Management Co. Trims Holdings in Sanofi (NASDAQ:SNY)

Northwestern Mutual Wealth Management Co. lowered its position in shares of Sanofi (NASDAQ:SNY) by 35.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,741 shares of the company’s stock after selling 19,245 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Sanofi were worth $1,686,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Dynamic Advisor Solutions LLC grew its position in shares of Sanofi by 39.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after purchasing an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC bought a new position in Sanofi during the second quarter valued at approximately $13,725,000. Mount Yale Investment Advisors LLC grew its holdings in Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after buying an additional 12,806 shares in the last quarter. Jennison Associates LLC increased its stake in Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after acquiring an additional 30,115 shares during the last quarter. Finally, Sei Investments Co. boosted its position in shares of Sanofi by 9.3% during the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after acquiring an additional 47,297 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SNY. Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Down 0.1 %

NASDAQ SNY opened at $55.47 on Friday. The company has a fifty day moving average of $55.52 and a two-hundred day moving average of $51.09. The firm has a market capitalization of $140.76 billion, a price-to-earnings ratio of 27.87, a PEG ratio of 1.58 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. During the same period in the prior year, the business posted $0.95 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts predict that Sanofi will post 4.26 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.